RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients

RET-rearranged LADC in our series tended to occur as bilateral disease with early visceral involvement, especially with KIF5B fusion. Treatment with cabozantinib achieved responses, including 1 complete response. However, further studies are required in this group of patients.